[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-compression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-compression":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,102,128,161,190,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":42,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100650026","phase-2-testosterone-therapy-with-or-without-finasteride-after-spinal-cord-injury-trt-sci-trial-100650026",false,"NCT07742553","Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","TRT-SCI","Inclusion Criteria:\n\n* Veterans eligible for care within the Veterans Health Administration (VHA)\n* Diagnosis of motor incomplete SCI (AIS C-D) for \\>24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology\n* Low total testosterone (\\\u003C300 nanograms\u002Fdecilliter \\[ng\u002FdL\\]) and\u002For low free testosterone (\\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign of low testosterone, defined as:\n\n  * decreased energy\n  * motivation\n  * initiative or self-confidence\n  * increased fatigue or tiredness\n  * reduced sexual desire or activity\n  * decreased spontaneous (e.g., morning) erections or erectile dysfunction\n  * loss of body hair or reduced shaving\n  * feeling sad or blue or having a depressed mood or a persistent low-grade depressive disorder (defined as a score of \\>3 on the Patient Health Questionnaire \\[PHQ\\]-2)\n  * hot flashes\n  * fatigue or irritability\n  * poor concentration or memory\n  * mild unexplained (normocytic-normochromic) anemia, defined as hematocrit (HCT) \\\u003C40%, hemoglobin \\\u003C13.6 grams\u002Fdeciliter (g\u002FdL), or red blood cell count \\\u003C4.5 million\u002Fmicroliter (mcL)\n  * sleep disturbances or increased sleepiness\n  * reduced muscle bulk, strength, or physical function\n  * increased body fat or body mass index\n* Presence of motor impairment, defined as self-selected walking pace ≤1.0 meters\u002Fsecond (m\u002Fs) on a 10-meter walk test (10mWT), with or without gait devices or braces and with or without assistance from another person, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairment identified by a trained observer\n* Medically stable condition asymptomatic for bladder infection, major decubiti, cardiopulmonary disease, or other significant condition that will interfere with the study\n* Documented approval from a physician verifying medical status\n\nExclusion Criteria:\n\n* Involvement in another research study that may influence outcomes\n* Mental state that precludes understanding the protocol\n* Life expectancy \\\u003C12 months\n* History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures\n* Amyotrophic lateral sclerosis, multiple sclerosis, or other neurologic injury \u002F impairment that may complicate procedures\n* Current cancer diagnosis\n* History of prostate or breast cancer\n* Any diagnosed or treated cancer in the past 24 months, except basal or squamous cell carcinoma of the skin that has been successfully treated\n* Any major lower-limb fracture in the past 12 months\n* Unevaluated circulating prostate-specific antigen (PSA) \\>4.0 nanograms\u002Fmilliliter (ng\u002FmL) or \\>3.0 ng\u002FmL in men with prostate cancer risk factors, including agent orange exposure, first degree relative with prostate cancer, or African American background\n* Currently seeking fertility or expected during the study\n* Diagnosed gynecomastia\n* Hematocrit (HCT) \\>48%\n* Any major cardiovascular event in the last 6 months, defined as:\n\n  * an acute myocardial infarction\n  * any cardiac revascularization procedure including stenting\n  * angioplasty or coronary artery bypass grafting\n  * revascularization of the carotid or middle cerebral artery or procedure to treat critical limb ischemia\n  * hospitalization due to unstable angina\n  * transient ischemic attack\n  * stroke\n  * peripheral vascular disease\n* Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV)\n* Poorly controlled hypertension when on medication (consistent systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg)\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram findings such as left bundle branch block or marked abnormality that precludes serial screening for occult ischemic events\n* History of unprovoked deep venous thrombosis, unprovoked pulmonary embolism, history of recurrent deep venous thrombosis or known thrombophilia\n* Major non-cardiovascular surgery (e.g., major abdominal or thoracic procedure) within 90 days before screening or a major surgery scheduled at the time of screening\n* Liver enzymes (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease defined as eGFR \\\u003C30 milliliters\u002Fminute (mL\u002Fmin)\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Use of an agent that alters sex-steroid metabolism in the past 90 days, such as: testosterone therapy (TRT), compounded or over-the-counter androgenic hormone or androgen precursor, 5-alpha reductase (5AR) inhibitors, growth hormone, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or others\n* Use of anti-resorptive or bone anabolic drug therapy in the past 180 days\n* Acute use (\\>5 days) of any opioid (e.g., oxycodone, hydrocodone) or systemic glucocorticoids \\>7.5 milligrams (mg)\u002Fday prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) in the week before screening, except for men who are taking these for a chronic condition and who are anticipated to continue these for the study duration\n* Known allergy to any TRT component (e.g., cottonseed oil or other)\n* Any other condition, lab abnormality, therapy, medical or psychiatric condition, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive a study intervention, or interfere with their ability to participate for the full study duration","MALE","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Spinal Cord Injury","Spinal Cord Injuries","Injuries, Spinal Cord","Spinal Cord Contusion","Spinal Cord Trauma","Trauma, Nervous System","Wounds and Injuries","Spinal Cord Compression","Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male",[43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,28,82,83,84,85,86,29,33,34,87,36,37,38,39,40,41,88],"Testosterone","Testosterone cypionate","Testosterone enanthate","Testosterone 17 beta-cypionate","Testosterone undecanoate","Methyltestosterone","Testosterone propionate","Dihydrotestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Therapy","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Lipid and Glucose profile","Muscle Strength","5-alpha Reductase","Muscle Mass","Bone Mineral Density","Adipose Tissue","Fat Mass","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Muscle, Skeletal","Bone and Bones","Gait","Walking","Locomotion","Motor Activity","Finasteride","Genital Diseases","Urogenital Diseases","Male Urogenital Diseases","Bone Diseases","Musculoskeletal Diseases","Central Nervous System Diseases","Steroids","NOT_YET_RECRUITING","2026-08-03",{"date":92,"type":93},"2026-08-04","ACTUAL",{"date":95,"type":21},"2027-10-01",{"date":97,"type":21},"2032-03-31",{"name":99,"class":100},"VA Office of Research and Development","FED",4,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":110,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100522013","miami-radar-trial-100522013","NCT06077071","Miami \"RADAR\" Trial","The Miami \"RADAR\" Trial - RAdiosurgical Debulking of Asymptomatic\u002FRadiographic Spinal Cord Compression","RADAR","Inclusion Criteria:\n\n1. Male and female participants ages ≥ 18.\n2. Solid tumors causing Metastatic epidural spinal cord compression (MESCC) for which surgery is an option as first-line treatment.\n3. Tumor histologies eligible for treatment include breast, prostate, sarcoma, melanoma, gastrointestinal types, NSCLC and renal cancers. Other solid malignancy types are also allowed at discretion of investigator if not specifically excluded by criteria.\n4. MRI of involved spine within 4 weeks prior to registration to determine extent of spine involvement.\n5. Bilsky scale ≥ 1c MESCC with tumor ≤ 1 mm from the spinal cord or cauda equina nerve roots anywhere from C1 to terminus of cauda equina on screening MRI.\n6. Protocol defined MESCC must involve no more than 3 contiguous vertebral levels. MESCC can involve multiple non-contiguous spinal canal regions within those 3 contiguous vertebral levels.\n7. Karnofsky performance score ≥60\n8. Survival prognosis ≥3 months\n9. Medical status allowing surgery.\n10. Neurologic exam within 1 week prior to registration and again within 1 week of first treatment to rule out severe neurologic deficits caused by disease at site of cord compression.\n11. Patients with mild to moderate cord neurologic signs are eligible if they are improved or stabilized by steroid. These neurologic signs include radiculopathy, dermatomal sensory change, and muscle strength of involved extremity 4\u002F5 (lower extremity for ambulation or upper extremity for raising arms and\u002For arm function).\n12. All patients must be ambulatory.\n13. Numerical Rating Pain Scale within 1 week prior to registration (back pain permitted for enrollment).\n14. Spine instability neoplastic score \\\u003C 14.\n\n    a. An exception to this criterion may be made if the patient is evaluated by a spinal surgeon and the surgeon defers surgery.\n15. Willing and able to undergo daily MRI during treatment.\n16. Willingness and able to use an acceptable method of contraception during the study and for at least 6 months after stopping the therapy.\n17. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n18. History and physical within 2 weeks prior to registration.\n19. Patients must provide study specific informed consent prior to study entry.\n\nExclusion Criteria:\n\n1. Unknown primary histology.\n2. Patients with rapid neurologic decline.\n3. Bony retropulsion causing neurologic abnormality.\n4. Non-ambulatory patients.\n5. Prior radiation to the involved site.\n6. Inability to have an MRI.\n7. Pre-existing or concomitant neurological problems not related directly to MESCC (e. g., neurologic deficits due to brain metastases).\n8. Very radiosensitive tumor histology (e.g., myeloma, seminoma, germ cell tumors, leukemia, and lymphoma).\n9. Patients with impaired decision-making capacity.","ALL",{"count":112,"type":21},10,[114],"NA","The purpose of this study is to see if treating cancer with radiation therapy administered by the Varian Ethos system can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).",[117,35],"Metastatic Epidural Spinal Cord Compression","2026-07-31",{"date":92,"type":93},{"date":121,"type":21},"2026-09-01",{"date":123,"type":21},"2028-09-01",{"name":125,"class":126},"University of Miami","OTHER",1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":110,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":127},"100441087","laser-interstitial-thermal-ablation-and-stereotactic-radiosurgery-for-patients-with-spine-metastases-100441087","NCT05023772","Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases","A Clinical Trial Evaluating the Efficacy of Combining Laser Interstitial Thermal Ablation With and Without Spine Stereotactic Radiosurgery for Patients With Spine Metastases","Inclusion Criteria:\n\n* Age \\> 18 years old. (The indication for this technique is controversial in skeletally immature patients.)\n* Histologic diagnosis of solid malignant tumor (not one of the more radiosensitive histologic subtypes, see Exclusion Criteria), including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors.\n* Quantification of the degree of epidural spinal cord compression as grade 1C, 2, or 3 by MRI, with and without contrast sequences. Axial T2 sequence is encouraged but not required.\n* The vertebral body site to be treated must be located from T2 to L1\n* No more than 3 contiguous or dis-contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session or 3 sessions.\n* Motor strength ≥4 out of 5 in extremity or extremities affected by the level of the spinal cord compression (see section 4 for grading method).\n* ECOG performance status \\\u003C2 or Karnofsky performance status (KPS) \\>50\n* Life expectancy \\>3 months.\n* Inoperable disease because of patient refusal, neurosurgical evaluation, or any other medical reasons.\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Prior conventional radiation to the same site is allowed as long as there is a greater than 3 months interval.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Requires open spinal procedure or a percutaneous procedure without the use of image guidance.\n* Primary tumors of radiosensitive histology (lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors), as conventional radiation is likely to be effective in such cases.\n* Unable to tolerate general anesthesia and prone position.\n* Unable to undergo MRI scan of the spine.\n* Inability to lie flat on a treatment table for \\>60 minutes.\n* Pregnant. (Urine testing must be done no more than 10 days prior to surgery.)\n* Prior conventional irradiation of the spine site and level to be treated with an interval shorter than 3 months.\n* Frank cord compression or cord compression from bone components or configuration and acute neurological deficits (defined as motor strength \\\u003C4\u002F5 in extremity or extremities affected by the level of the spinal cord compression)",{"count":136,"type":21},60,[114],"The purpose of this research is to combine two complementary modes of treatment, spinal interstitial laser ablation and stereotactic spine radiosurgery (SSRS) for the treatment for spinal tumors near the spinal cord with an objective to improve tumor control, improve pain control, preserve function, and improve quality of life. We will also assess how effective these combined modes of treatment are in patients with spinal metastasis with an epidural component.",[140,37,35,141,142],"Neoplasm Metastasis","Spinal Cord Tumor","Spine Metastases",[144,145,146,147,148,149,150],"Laser Ablation","Spinal Cord","Minimally Invasive Surgical Procedure","Stereotactic Radiosurgery","Pain Control","Metastasis","Epidural Tumor","RECRUITING","2026-06-02",{"date":154,"type":93},"2026-06-03",{"date":156,"type":93},"2021-09-02",{"date":158,"type":21},"2028-06-20",{"name":160,"class":126},"Henry Ford Health System",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":110,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":188,"locationsCount":127},"100627457","validity-of-the-turkish-translation-of-the-modified-joa-100627457","NCT07448883","Validity of the Turkish Translation of the Modified JOA","Validity, Reliability, and Clinical Correlation Study of the Turkish Translation of the Modified JOA (Japanese Orthopedic Association) Cervical Myelopathy Score","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Patients diagnosed with degenerative cervical myelopathy using clinical or magnetic resonance imaging\n* Able to provide written informed consent to participate in the study\n* Cognitive competence to understand Turkish forms and scales\n\nExclusion Criteria:\n\n* Spinal cord injury due to trauma, tumor, infection, inflammatory diseases, etc., pathologies\n* Previous cervical surgery\n* Severe cognitive impairment or communication problems that would prevent participation in the study\n* Subjects who were informed about the study but refused to participate",{"count":169,"type":21},70,"1 Month","OBSERVATIONAL","Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord dysfunction in adults and may lead to progressive motor, sensory, and autonomic impairment. Accurate and standardized assessment of neurological function is essential for clinical decision-making, prognostic evaluation, and comparison of treatment outcomes. The Modified Japanese Orthopaedic Association (mJOA) score is one of the most widely used clinician-based outcome measures for evaluating neurological status in patients with DCM. Although the mJOA has been translated and validated in several languages, no validated Turkish version currently exists.\n\nThis prospective, cross-sectional validation study aims to culturally adapt the mJOA score into Turkish and evaluate its validity, reliability, and clinical correlation in Turkish-speaking patients diagnosed with DCM. Adult patients (≥18 years) with clinically and radiologically confirmed DCM presenting to the outpatient clinics of Physical Medicine and Rehabilitation and Neurosurgery will be included. Previously obtained cervical magnetic resonance imaging will be reviewed retrospectively to determine myelomalacia levels, while clinical scales will be administered prospectively.\n\nConstruct validity will be assessed by examining correlations between the Turkish mJOA scores and the Neck Disability Index, as well as the Nurick grading system. Inter-rater reliability will be evaluated using the Intraclass Correlation Coefficient (ICC \\[2,1\\]) between two independent evaluators, and test-retest reliability will be assessed in clinically stable patients after 7-14 days. Feasibility will be evaluated by recording the administration time and potential difficulties during application.\n\nThis study is expected to provide a valid and reliable Turkish version of the mJOA score, facilitating standardized assessment of DCM in Turkish clinical practice and enabling comparability with international research.",[174,35],"Spondylosis, Cervical",[176,177,178,179,180,181],"Degenerative Cervical Myelopathy","Cervical Spondylotic Myelopathy","Modified Japanese Orthopaedic Association Score","mJOA","Reliability","Neck Disability Index","2026-05-10",{"date":184,"type":93},"2026-05-13",{"date":182,"type":93},{"date":187,"type":21},"2027-05-30",{"name":189,"class":126},"Izmir Democracy University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":110,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100633518","postoperative-neurological-recovery-and-risk-factor-analysis-in-patients-with-paralysis-due-to-spinal-metastases-100633518","NCT07527728","Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases","Inclusion Criteria:\n\n1. Age between 18 and 80 years at the time of enrollment.\n2. Clinical diagnosis of spinal metastases with resulting motor paralysis.\n3. Scheduled for surgical decompression and\u002For spinal stabilization.\n4. Medically fit to undergo surgery as determined by preoperative evaluation.\n5. Ability to understand the study and provide written informed consent.\n6. Willingness and ability to complete neurological and functional follow-up assessments.\n\nExclusion Criteria:\n\n1. Medically unfit for surgery due to unstable comorbidities or poor general condition.\n2. Pregnant or breastfeeding at the time of enrollment.\n3. Significant cognitive impairment or psychiatric illness that interferes with informed consent or study participation.\n4. Expected difficulty in completing follow-up assessments or anticipated loss to follow-up.\n5. Missing critical baseline or follow-up data relevant to study endpoints.",{"count":197,"type":21},150,"Metastatic spinal tumors represent a common and devastating complication in patients with advanced solid malignancies. Up to 40% of cancer patients may develop spinal metastases during the course of their disease, often resulting in intractable pain, neurological deficits, and spinal instability. One of the most serious consequences is motor paralysis caused by metastatic epidural spinal cord compression (MESCC), which can severely impair patients' quality of life and limit their ability to receive subsequent anti-tumor therapy. Although surgical decompression and stabilization are recognized as effective strategies for relieving spinal cord compression and restoring spinal integrity, the neurological prognosis for patients who present with paralysis remains uncertain and heterogeneous.\n\nThis prospective, single-center, observational cohort study aims to evaluate the early and mid-term neurological recovery trajectories in patients with paralysis caused by spinal metastases, and to identify perioperative clinical factors associated with favorable or poor functional outcomes. The study will be conducted at Shanghai Changzheng Hospital, a tertiary care academic center with extensive experience in spinal oncology and multidisciplinary cancer care.\n\nThe investigators plan to consecutively enroll adult patients (aged 18-80) diagnosed with spinal metastatic tumors who present with motor paralysis and are deemed appropriate surgical candidates by a multidisciplinary tumor board. Participants will undergo surgical decompression and stabilization based on individualized tumor location and spinal instability. The study does not involve any investigational drug or device. All surgical procedures and adjuvant treatments (such as radiotherapy or systemic therapy) will be delivered according to standard of care.\n\nPreoperative evaluations will include spinal imaging (MRI, CT), neurological scoring using the ASIA Impairment Scale, and assessments of systemic condition, spinal instability (SINS), and epidural compression severity (ESCC scale). Participants will be followed at 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery to monitor neurological recovery, pain control, bowel\u002Fbladder function, treatment complications, and survival.\n\nThe primary outcome is the improvement in motor function at 1 month postoperatively, quantified by changes in ASIA motor scores. Secondary outcomes include longer-term neurological recovery, progression of bowel and bladder function, quality of life, complication rates, disease progression, and survival outcomes. Additional analyses will explore the impact of variables such as timing of surgery, tumor histology, location of compression, and performance status on recovery.\n\nThis study will employ both univariate and multivariate statistical methods to identify independent predictors of postoperative neurological improvement, using logistic regression and time-to-event analyses. A total of 150 participants will be recruited, based on power analysis accounting for key covariates and anticipated dropout rates.\n\nThrough this prospective clinical registry and analysis, the study aims to provide evidence-based data to guide clinical decision-making in the management of MESCC with paralysis. The findings will help inform surgical indications, optimize timing of intervention, and support the development of prognostic tools for patient counseling. Given the limited life expectancy of many patients with advanced cancer, maximizing early neurological recovery may directly impact patient autonomy, eligibility for systemic therapy, and overall quality of life.",[200,35,201,202],"Metastatic Spinal Tumors","Paralysis","Neurological Deficits","2026-04-09",{"date":205,"type":93},"2026-04-14",{"date":207,"type":21},"2026-05-01",{"date":209,"type":21},"2028-06-30",{"name":211,"class":126},"Shanghai Changzheng Hospital",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":110,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":127},"100310391","enhancing-recovery-in-non-traumatic-spinal-cord-injury-100310391","NCT03320759","Enhancing Recovery in Non-Traumatic Spinal Cord Injury","Enhancing Recovery in Non-Traumatic Spinal Cord Injury: Implementation of an Integrated Program for the Assessment of Rehabilitation Therapies","Inclusion Criteria:\n\n* right-handed\n* have a history of progressive neurological deficits \\\u003C24 months\n* eligible for MRI scanning\n\nExclusion Criteria:\n\n* having any other neurological disorder or systemic disease that can impair neurological function\n* not fluent in reading and speaking English\n* being claustrophobic\n* unable to follow simple task instructions and maintain standardized movements\n* being unable to return for all follow-up imaging and rehabilitation sessions",{"count":220,"type":21},40,[114],"The investigators have spent the last decade uncovering unique metabolic and functional abnormalities in the brains of patients with spinal cord compression. Degenerative spinal cord compression represents a unique model of reversible spinal cord injury. In the investigator's previous work, they have demonstrated that cortical reorganization and recruitment is associated with metabolic changes in the brains of patients recovering from spinal cord compression and is correlated with recovery and improved neurological scores.\n\nThe goal of this study is to combine a rigorous platform of clinical care that includes preoperative evaluation, surgery, and rehabilitation, with state of the art imaging techniques to demonstrate how rehabilitative therapy can increase brain plasticity and recovery of neurological function in patients with spinal cord injury. Neurological function will be carefully evaluated in two groups of patients, those receiving rehabilitation and those not receiving rehabilitation after spine surgery, and will be correlated with the results of advanced imaging.",[35,29,224,225],"Cervical Spondylosis","Myelopathy Cervical","2024-03-26",{"date":228,"type":93},"2024-03-28",{"date":230,"type":93},"2018-08-21",{"date":232,"type":21},"2026-07-01",{"name":234,"class":126},"Western University, Canada"]